Compare SUVEN LIFE with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES GSK PHARMA SUVEN LIFESCIENCES/
GSK PHARMA
 
P/E (TTM) x 4.4 228.6 1.9% View Chart
P/BV x 0.6 11.8 5.5% View Chart
Dividend Yield % 3.6 1.3 264.9%  

Financials

 SUVEN LIFESCIENCES   GSK PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
GSK PHARMA
Mar-19
SUVEN LIFESCIENCES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3383,595 9.4%   
Low Rs1691,253 13.5%   
Sales per share (Unadj.) Rs52.1184.7 28.2%  
Earnings per share (Unadj.) Rs6.826.3 26.0%  
Cash flow per share (Unadj.) Rs8.629.2 29.4%  
Dividends per share (Unadj.) Rs1.5020.00 7.5%  
Dividend yield (eoy) %0.60.8 71.7%  
Book value per share (Unadj.) Rs65.3126.3 51.7%  
Shares outstanding (eoy) m127.28169.40 75.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.913.1 37.1%   
Avg P/E ratio x37.192.2 40.3%  
P/CF ratio (eoy) x29.683.1 35.6%  
Price / Book Value ratio x3.919.2 20.2%  
Dividend payout %22.076.1 28.9%   
Avg Mkt Cap Rs m32,272410,626 7.9%   
No. of employees `0001.15.0 21.8%   
Total wages/salary Rs m6615,372 12.3%   
Avg. sales/employee Rs Th6,132.26,306.7 97.2%   
Avg. wages/employee Rs Th611.11,083.1 56.4%   
Avg. net profit/employee Rs Th803.5898.0 89.5%   
INCOME DATA
Net Sales Rs m6,63531,281 21.2%  
Other income Rs m2421,023 23.7%   
Total revenues Rs m6,87732,304 21.3%   
Gross profit Rs m1,6046,009 26.7%  
Depreciation Rs m221486 45.6%   
Interest Rs m386 628.3%   
Profit before tax Rs m1,5876,540 24.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m7182,373 30.3%   
Profit after tax Rs m8694,454 19.5%  
Gross profit margin %24.219.2 125.9%  
Effective tax rate %45.236.3 124.7%   
Net profit margin %13.114.2 92.0%  
BALANCE SHEET DATA
Current assets Rs m6,23220,061 31.1%   
Current liabilities Rs m1,49014,543 10.2%   
Net working cap to sales %71.517.6 405.2%  
Current ratio x4.21.4 303.2%  
Inventory Days Days8657 152.2%  
Debtors Days Days8314 587.5%  
Net fixed assets Rs m4,04314,343 28.2%   
Share capital Rs m1271,694 7.5%   
"Free" reserves Rs m8,18319,704 41.5%   
Net worth Rs m8,31021,398 38.8%   
Long term debt Rs m182 890.0%   
Total assets Rs m10,38939,113 26.6%  
Interest coverage x43.11,091.0 4.0%   
Debt to equity ratio x00 2,291.8%  
Sales to assets ratio x0.60.8 79.9%   
Return on assets %8.711.4 76.6%  
Return on equity %10.520.8 50.3%  
Return on capital %19.531.9 61.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,622534 1,052.8%   
Fx outflow Rs m1,7997,091 25.4%   
Net fx Rs m3,822-6,557 -58.3%   
CASH FLOW
From Operations Rs m3563,994 8.9%  
From Investments Rs m-279-1,433 19.4%  
From Financial Activity Rs m-225-3,584 6.3%  
Net Cashflow Rs m-148-1,023 14.5%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.0 10.2 -  
FIIs % 0.0 23.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 15.4 237.0%  
Shareholders   37,287 102,036 36.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   SANOFI INDIA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  CIPLA  ASTRAZENECA PHARMA  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Metal and Telecom Stocks Witness Buying(Closing)

Indian share markets continued to trade on a volatile note and ended on a flat note today. At the closing bell, the BSE Sensex stood lower by 24 points (down 0.1%).

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

My Best Trading Ideas When Interest Rates Are So Low(Fast Profits Daily)

Jul 23, 2020

India's interest rates are lower than the inflation rate. Here are the best trades for this situation.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Gold or Silver: Which One Should You Buy Now?(Fast Profits Daily)

Jul 24, 2020

Silver and gold are both vying for your attention. Which is the better trade today?

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Aug 5, 2020 03:37 PM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS